NEW YORK (GenomeWeb News) – BGI and H3 Biomedicine today announced they will sequence and publish data from next-generation sequencing-based research on pre-clinical cancer models.

In the first study to be performed under the terms of the partnership, BGI will sequence 250 cancer cell lines using next-generation whole-exome sequencing. It and H3 Biomedicine will jointly analyze the data and then deliver a highly curated set of "genetically profiled, pre-clinical model information that will help to accelerate drug discovery and development efforts."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The World Health Organization calls for the public release of clinical trial results within a year of the completion of data collection.

In Science this week: measles virus nucleocapsid structure, and more.

African and US health officials work to establish an Africa-wide Centres for Disease Control and Prevention.

Nature has retracted a 2002 epigenetics paper for image manipulation.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.